Navigation Links
SpectraCell Now Offers LPP™ Cardiovascular Testing in New York
Date:4/28/2011

HOUSTON, April 28, 2011 /PRNewswire/ -- SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to New York state physicians and patients.  The recently patented LPP™ test has been commercially available to the other 49 states since 2006.

SpectraCell began the process of acquiring a licensure in 2008 with an application submission to the state of New York.  The laboratory underwent an initial inspection by the New York State Department of Health in late 2009 followed by extensive documentation validating the LPP™ procedure, which is standard protocol required of all diagnostic laboratories.  A final inspection in December 2010 concluded the evidentiary process, proving the LPP™ technology is valid, accurate and reproducible.

"Acquiring our New York license allows us to serve the largest metropolitan area in the country," states Dr. Fred Crawford, Ph.D., VP of Operations and Laboratory Director at SpectraCell Labs. "In fact, many physicians in the state of New York have wanted to implement the LPP™ test in their practice but were unable to do so until now.  Plus, we recently streamlined our LPP™ report using feedback from existing LPP™ clients, making it easier than ever for physicians to translate LPP™ results into clinical decisions."

New York represents a large market for laboratory testing.  According to a CNN report, approximately 40,000 physicians practice within a 30 mile radius of New York City, in contrast to a national average of about 8000 physicians for other American cities.

After visiting the laboratory and reviewing the testing protocol, Dr. Robert Rej, Director of Chemistry for the State of New York Department of Health recommended the permit be approved for SpectraCell's LPP™ testing. The license also allows SpectraCell to add FDA approved chemistry procedures to New York clients.  Their first addition will be LpPLA2 testing (lipoprotein-associated phospholipase A2) which measures a specific enzyme linked to thrombosis (blood clots), indicating a higher risk of heart attack or stroke.  

Just a few months ago, SpectraCell Laboratories was awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test, which measures both the size and number of lipoproteins rather than the cholesterol contained within them.  In recent years, more doctors have seen standard cholesterol tests label a patient "normal" when in reality their risk for heart disease is quite high.

In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have "normal" cholesterol – that is, cholesterol below 200 mg/dL.  The LPP™ test allows physicians to stratify risk more accurately, thus prescribing therapies that will be the most effective, depending on their patients' specific lipid profile.

NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:

  1. RLP – (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
  2. Lp(a) – a dangerous lipoprotein that contributes to clot formation
  3. HDL2b – a type of HDL that indicates how well cholesterol is being cleared from your system
  4. Small, dense LDL – easily penetrates vascular wall, causing damage and plaque

The LPP™ is part of the trend toward more individualized medicine. The LPP™ test, which is done on a fasting blood sample, is usually covered by insurance.  Results typically take 3-5 days. For more information, go to www.spectracell.com.

About SpectraCell Laboratories – SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing such as micronutrient testing, telomere analysis, Omega 3 Index and the Lipoprotein Particle Profile™ (LPP™).

SpectraCell's Lipoprotein Particle Profile™ is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell's LPP™ directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dr. Fred Crawford, Ph.D.

http://www.profnetconnect.com/drj_fredcrawfordphd


'/>"/>
SOURCE SpectraCell Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraCell Contracts With Beech Street Corporation
2. SCAN Health Plan Offers Seniors Five Tips to Prepare for Surgery
3. BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts
4. Minnesota Chiropractic Association Offers Backpack Safety Checklist
5. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
6. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Friends of the Earth Report on Biofuel Production Offers Incomplete, Outdated and Inaccurate Picture, According to Brazilian Sugarcane Industry Association
9. ProSource 2.0 Offers Value, Savings for Lab Supplies
10. KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals
11. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder and ... of the 2017 IAC Awards at the 22nd World Congress on Heart Disease held ... four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ ... board of directors. This addition continues to strengthen and diversify VIC’s board. , ... and Chairman. “He is a highly accomplished business executive with a broad range of ...
(Date:7/20/2017)... DENVER and PLYMOUTH, Minn., July 20, 2017 ... LLC , a personalized genetic evaluations company, today ... under their partnership investigating a genetic mutation implicated ... to extend the partnership for a second case ... Last year, the KCNQ2 Cure Alliance and Pairnomix ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... solution to make clinical trial sites and study participants truly unified. TrialKit, a ... compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. With ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):